Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

T Lane Folse

Internal Medicine Baker, LA Medical Doctor

NPI 1750331997 CMS profile 34394

6516 E Myrtle Ave, Baker, LA 70714

Open in the dashboard

General payments

$3,478

212 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, T Lane Folse of Baker, LA is reported in the CMS Open Payments database as having received $3,478 across 212 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 85th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $272 16
2024 General $412 20
2023 General $482 30
2022 General $875 53
2021 General $601 36
2020 General $264 17
2019 General $572 40

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • T Lane Folse
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to T Lane Folse were reported at $272. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year T Lane Folse Internal Medicine median Middle half National median
2019 $572 $159 $48–$570 $163
2020 $264 $119 $33–$402 $114
2021 $601 $135 $37–$521 $132
2022 $875 $141 $42–$496 $149
2023 $482 $149 $45–$519 $160
2024 $412 $154 $47–$537 $164
2025 $272 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $521 33 payments
  2. Lilly USA, LLC $448 35 payments
  3. Takeda Pharmaceuticals U.S.A., Inc. $287 15 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $271 14 payments
  5. Pfizer Inc. $198 12 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $169 11 payments
  7. Amgen Inc. $168 10 payments
  8. Janssen Pharmaceuticals, Inc $145 10 payments
  9. Merck Sharp & Dohme Corporation $143 10 payments
  10. AbbVie, Inc. $137 9 payments
  11. Other $992 53 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,478 212 payments
Products named General payments · program years 2019–2025
  1. Ozempic $401 25 payments
  2. RYBELSUS $329 20 payments
  3. MOUNJARO $315 24 payments
  4. Kerendia $271 14 payments
  5. VYVANSE $156 9 payments
  6. JARDIANCE $153 10 payments
  7. XARELTO $145 10 payments
  8. TRINTELLIX $144 7 payments
  9. TRULICITY $132 11 payments
  10. iLet Bionic Pancreas $124 1 payment
  11. Other $3,204 192 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 107 drugs

Part D claims

5,743

Median for Internal Medicine: 777

Drug cost

$429,811

Median for Internal Medicine: $73,373

Branded share of claims

22.9%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Januvia Sitagliptin Phosphate Brand 103 $85,554
Ozempic Semaglutide Brand 67 $75,252
Mounjaro Tirzepatide Brand 32 $67,384
Jardiance Empagliflozin Brand 35 $43,118
Eliquis Apixaban Brand 31 $36,371
Rybelsus Semaglutide Brand 13 $20,928
Trulicity Dulaglutide Brand 15 $15,809
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 25 $14,222
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 16 $12,587
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 39 $5,633

The 10 drugs with the highest cost, of 107 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 58 billing codes

Paid by Medicare

$55,681

Of which drugs: $11,782

Medicare patients

128

Average age 73

Services billed

1,081

86 women, 42 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 53%
Diabetes 42%
Depression 35%
Ischemic heart disease 30%
Chronic kidney disease 23%
COPD 17%
Atrial fibrillation 16%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Sarscv2 vac 30mcg trs-suc im 91320 Office 30 32 $4,816
Vaccine for influenza for injection into muscle 90662 Office 46 47 $3,816

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 7 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $90
$90 32 —
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $45
$45 — —
ZEPBOUND
  • Lilly USA, LLC $40
$40 — —
JARDIANCE
  • Boehringer Ingelheim Pharmaceuticals, Inc. $16
  • Lilly USA, LLC $8
$23 35 —
KEVEYIS
  • Xeris Pharmaceuticals, Inc. $20
$20 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 7 in the dashboard with a free account

Records

212 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record